Amarin Corp Plcuk (AMRN) Enterprise Value (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Enterprise Value of -$177.0 million for Q1 2026, down 8.88% YoY from -$194.3 million in Q1 2025, and up 41.5% sequentially from -$302.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Enterprise Value (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Enterprise Value across 17 years of filings, most recently posting -$177.0 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 8.88% year-over-year to -$177.0 million; the TTM figure through Mar 2026 stood at -$177.0 million (down 8.88% YoY), while the FY2025 annual figure was -$302.6 million, down 74.42% from the prior year.
- Enterprise Value grew to -$177.0 million in Q1 2026, from -$302.6 million in the prior quarter.
- Over the last five years, Enterprise Value for AMRN reached as high as -$50.4 million in Q3 2023 and fell as low as -$362.6 million in Q1 2022.
- The 5-year median for Enterprise Value is -$173.5 million (2024), against an average of -$198.7 million.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 85.99% — and 2024, when it slumped 506.86%.
- A 5-year view of Enterprise Value shows it stood at -$92.2 million in 2022, then plunged by 32.22% to -$121.9 million in 2023, then sank by 42.28% to -$173.5 million in 2024, then slumped by 74.42% to -$302.6 million in 2025, then jumped by 41.5% to -$177.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$177.0 million, -$302.6 million, and -$164.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.35 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -7.89 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 315.00 Mn |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -177.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.00 Mn |
| Dec 31, 2025 | -302.59 Mn |
| Sep 30, 2025 | -164.10 Mn |
| Jun 30, 2025 | -298.70 Mn |
| Mar 31, 2025 | -162.56 Mn |
| Dec 31, 2024 | -173.48 Mn |
| Sep 30, 2024 | -305.69 Mn |
| Jun 30, 2024 | -306.60 Mn |
| Mar 31, 2024 | -94.76 Mn |
| Dec 31, 2023 | -121.93 Mn |
| Sep 30, 2023 | -50.37 Mn |
| Jun 30, 2023 | -80.42 Mn |
| Mar 31, 2023 | -304.37 Mn |
| Dec 31, 2022 | -92.22 Mn |
| Sep 30, 2022 | -67.12 Mn |
| Jun 30, 2022 | -313.23 Mn |
| Mar 31, 2022 | -362.61 Mn |
| Dec 31, 2021 | -454.13 Mn |
| Sep 30, 2021 | -479.20 Mn |
| Jun 30, 2021 | -185.83 Mn |